SCH900776 S-isomer

• CAT Number: I005339
• CAS Number: 891494-64-7
• Molecular Formula: C15H18BrN7
• Molecular Weight: 376.25
• Purity: ≥95%
• Synonyms: (S)-6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine
• Target: Cyclin-Dependent Kinases
• Solubility: DMSO > 50 mg/mL Ethanol 3 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
• InChI: InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3/t9-/m0/s1
• InChIKey: GMIZZEXBPRLVIV-VIFPVBQESA-N
• SMILES: CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)[C@H]4CCCNC4

SCH900776 S-isomer（Cat No.:I005339）is a selective inhibitor of the enzyme Janus kinase 1 (JAK1), which plays a critical role in cytokine signaling and immune cell function. By inhibiting JAK1, SCH900776 S-isomer aims to modulate the immune response, making it a potential treatment for autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD). The S-isomer form of the compound is specifically designed to optimize its pharmacokinetic properties and potency. Early preclinical and clinical studies have shown promise, but further research is needed to assess its safety, efficacy, and long-term therapeutic potential.

Reference

[1]. Montano R, Chung I, Garner KM, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012 Feb;11(2):427-38.
[2]. Judith E. Karp, Brian M. Thomas, et al. Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clin Cancer Res; 2012, 18(24); 6723-31.
[3]. Thompson R, Montano R, Eastman A. The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition. PLoS One. 2012;7(8):e44021.
[4]. Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
[5]. Paruch K, Dwyer MP, Alvarez C, et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 2010;1:204-8.
[6]. Dwyer MP, Paruch K, Alvarez C, et al. Versatile templates for the development of novel kinase inhibitors: discovery of novel CDK inhibitors. Bioorg Med Chem Lett 2007;17: 6216-9.